06:48:19 Europe / Stockholm

Attachments

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2025-02-20 Year-end Report 2024
2024-11-21 Quarterly Report 2024-Q3
2024-08-22 Quarterly Report 2024-Q2
2024-05-24 Ex-date Ordinary Dividend DIGN 0.00 SEK
2024-05-23 Annual General meeting
2024-05-23 Quarterly Report 2024-Q1
2024-03-12 Extra General Meeting 2024
2024-02-15 Year-end Report 2023
2023-11-16 Quarterly Report 2023-Q3
2023-08-17 Quarterly Report 2023-Q2
2023-05-26 Ex-date Ordinary Dividend DIGN 0.00 SEK
2023-05-25 Quarterly Report 2023-Q1
2023-05-25 Annual General meeting
2023-02-16 Year-end Report 2022
2022-11-17 Quarterly Report 2022-Q3
2022-08-18 Quarterly Report 2022-Q2
2022-05-20 Ex-date Ordinary Dividend DIGN 0.00 SEK
2022-05-19 Annual General meeting
2022-05-19 Quarterly Report 2022-Q1
2022-02-17 Year-end Report 2021
2021-11-18 Quarterly Report 2021-Q3
2021-08-19 Quarterly Report 2021-Q2
2021-05-21 Ex-date Ordinary Dividend DIGN 0.00 SEK
2021-05-20 Annual General meeting
2021-05-20 Quarterly Report 2021-Q1
2021-02-18 Year-end Report 2020
2021-01-11 Extra General Meeting 2021
2020-11-19 Quarterly Report 2020-Q3
2020-08-20 Quarterly Report 2020-Q2
2020-06-26 Ex-date Ordinary Dividend DIGN 0.00 SEK
2020-06-25 Annual General meeting
2020-05-28 Quarterly Report 2020-Q1
2020-02-25 Year-end Report 2019
2020-02-10 Extra General Meeting 2019
2019-11-19 Quarterly Report 2019-Q3
2019-08-22 Quarterly Report 2019-Q2
2019-05-16 Ex-date Ordinary Dividend DIGN 0.00 SEK
2019-05-16 Quarterly Report 2019-Q1
2019-05-15 Annual General meeting
2019-02-26 Year-end Report 2018
2018-11-27 Quarterly Report 2018-Q3
2018-08-21 Quarterly Report 2018-Q2
2018-05-22 Quarterly Report 2018-Q1
2018-04-27 Ex-date Ordinary Dividend DIGN 0.00 SEK
2018-04-26 Annual General meeting
2018-02-22 Year-end Report 2017
2017-12-04 Extra General Meeting 2017
2017-11-23 Quarterly Report 2017-Q3
2017-08-24 Quarterly Report 2017-Q2
2017-06-02 Annual General meeting
2017-05-24 Quarterly Report 2017-Q1
2017-02-23 Year-end Report 2016
2016-11-24 Quarterly Report 2016-Q3
2016-08-25 Quarterly Report 2016-Q2
2016-05-25 Quarterly Report 2016-Q1
2016-03-23 Ex-date Ordinary Dividend DIGN 0.00 SEK
2016-03-22 Annual General meeting
2016-02-24 Year-end Report 2015
2015-11-25 Quarterly Report 2015-Q3
2015-08-26 Quarterly Report 2015-Q2
2015-05-27 Quarterly Report 2015-Q1
2015-05-19 Ex-date Ordinary Dividend DIGN 0.00 SEK
2015-02-24 Year-end Report 2014
2014-11-25 Quarterly Report 2014-Q3
2014-08-26 Quarterly Report 2014-Q2
2014-05-20 Quarterly Report 2014-Q1
2014-05-19 Ex-date Ordinary Dividend DIGN 0.00 SEK
2014-05-16 Annual General meeting
2014-03-04 Extra General Meeting 2014
2014-02-27 Year-end Report 2013
2013-11-28 Quarterly Report 2013-Q3
2013-08-28 Quarterly Report 2013-Q2
2013-08-28 Extra General Meeting 2013
2013-05-22 Quarterly Report 2013-Q1
2013-05-22 Ex-date Ordinary Dividend DIGN 0.00 SEK
2013-05-21 Annual General meeting
2013-02-27 Year-end Report 2012
2012-11-28 Quarterly Report 2012-Q3
2012-10-30 Extra General Meeting 2012
2012-09-28 Capital Market Day 2012
2012-08-28 Quarterly Report 2012-Q2
2012-06-29 Annual General meeting
2012-05-28 Quarterly Report 2012-Q1
2012-02-27 Year-end Report 2011
2011-11-17 Quarterly Report 2011-Q3
2011-08-22 Quarterly Report 2011-Q2
2011-06-13 Ex-date Ordinary Dividend DIGN 0.00 SEK
2011-06-10 Annual General meeting
2011-05-30 Quarterly Report 2011-Q1
2011-02-25 Year-end Report 2010
2010-11-18 Quarterly Report 2010-Q3
2010-08-19 Quarterly Report 2010-Q2
2010-06-21 Ex-date Ordinary Dividend DIGN 0.00 SEK
2010-05-18 Quarterly Report 2010-Q1
2010-02-18 Year-end Report 2009
2009-12-21 Split DIGN 100:1
2009-11-18 Quarterly Report 2009-Q3

Description

CountrySweden
ListFirst North Stockholm
SectorHealth care
IndustryMedical technology
Dignitana är verksamt inom medicinteknik. Bolaget utvecklar, tillverkar och marknadsför medicinska hjälpmedel som primärt används som skalpkylningssystem vid cytostatikabehandling, vars syfte är att eliminera eller kraftigt reducera håravfall. Bolaget har global verksamhet främst inom Norden, Europa, Nordamerika och Asien. Dignitana grundades år 2007 och har sitt huvudkontor i Lund.
2023-11-07 11:00:00

Dignitana AB announces today that the US Centers for Medicare & Medicaid Services (CMS) has published the  OPPS Final Rule (https://www.cms.gov/newsroom/fact-sheets/cy-2024-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center-0#:~:text=In%20the%20CY%202024%20OPPS%20and%20ASC%20PPS%20Final%20Rule,that%20is%20not%20an%20REH.), which continues to support scalp cooling but decreases the average rate from $1850.50 to $1250.50 under the  Hospital Outpatient Prospective Payment System (OPPS) and the  Ambulatory Surgery Center (ASC) payment system for Calendar Year (CY) 2024.

Although the 2024 rate is lower, the Final Rule does continue to support the consistent use of the 0662T CPT code, which is important to allow practices to bill for scalp cooling services and ensure access to scalp cooling for patients with Medicare coverage.

This action was based on claims data from 2021, which was the first year the scalp cooling CPT codes became effective. Fewer than 5 percent of the over 75 providers currently filing claims for scalp cooling were doing so in 2022. This directly supports our assertion that a larger data pool will be available to better inform accurate rate setting for CY 2025. When the CY 2024 proposed rule was published in July 2023 Dignitana and Paxman worked in collaboration to appeal the payment rate decrease, stating to CMS that the data represented only a small volume of claims that did not provide sufficient cost data to inform a change in rate setting at this time.

"We are committed to advancing scalp cooling to standard of care so that all patients have access to scalp cooling," said Dignitana CEO Catarina Löwenadler. "While we are disappointed to see that CMS did not accept our request to maintain the rate for 2024, we are pleased that growing number of providers are now adopting our Buy and Bill model so they can bill for the scalp cooling service they are administering. We believe that data from claims filed in 2022 will illustrate to CMS that this therapy merits stronger support in 2025."

Reimbursement for scalp cooling was initiated in 2021 with the introduction of the two CPT codes, 0662T and 0663T. Since that time commercial payers have responded favorably to the new coding in claims filed by providers.  A review of scalp cooling claims filed through August 2023 with code 0662T indicates that commercial plans are paying well above Medicare rates for this covered benefit. An analysis of claims filed in 2022 and 2023 by Paxman and Dignitana providers found that 71 percent of claims filed resulted in positive coverage.  For commercial payers reimbursing providers for code 0662T, the range of payments is $928 - $4857 per patient, with an additional reimbursement under the second 0663T code of $78 - $1200 for each treatment. Further review shows that fewer than 15 percent of patients currently receiving scalp cooling are over 65 and would be Medicare eligible.